Kiora Pharmaceuticals (NASDAQ:KPRX) Announces Quarterly Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) released its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.10, FiscalAI reports. The firm had revenue of $1.00 million for the quarter.

Kiora Pharmaceuticals Stock Down 1.5%

KPRX traded down $0.02 during trading on Thursday, hitting $1.33. The company’s stock had a trading volume of 20,641 shares, compared to its average volume of 64,861. The business’s 50 day simple moving average is $2.31 and its 200-day simple moving average is $2.38. Kiora Pharmaceuticals has a one year low of $1.33 and a one year high of $2.91.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research report on Monday, October 12th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Kiora Pharmaceuticals presently has a consensus rating of “Sell”.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.